Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1932 - Early drop of LV ejection fraction can predict trastuzumab-related cardiotoxicity in patients with breast cancer (63P)


18 Nov 2017


Poster lunch


Cytotoxic Therapy;  Supportive Care and Symptom Management;  Breast Cancer


Jinhyun Cho


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


J. Cho1, E.K. Kim2, K.H. Yoo3, H. Lee4, H.K. Kim4, M.H. Heo5, J. Park1, J.S. Ahn4, Y. Im4, Y.H. Park4

Author affiliations

  • 1 Hematology-oncology, Inha University Hospital, 22332 - Incheon/KR
  • 2 Cardiology, Samsung Medical Center, 06351 - Seoul/KR
  • 3 Hematology-oncology, Gil Medical Center, 22332 - Incheon/KR
  • 4 Division Of Hematology-oncology, Department Of Medicine, Samsung Medical Center, 06351 - Seoul/KR
  • 5 Hematology-oncology, Keimyung University Dongsan Medical Center, 41931 - Daegu/KR


Abstract 1932


While concerns about trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer (BRCA) increasing, there is a lack of evidences to support current recommendation to monitor TRCD. Especially, in Asian population, clinical manifestations and predictors of TRCD were unknown. Therefore, we aimed to identify characteristics and predictors of TRCD in Asian patients with BRCA.


From 2003 to 2016, consecutive 1371 patients who treated with adjuvant trastuzumab for BRCA were enrolled. We excluded patients with metastatic BRCA, number of trastuzumab administration 10% in left ventricular ejection fraction (LVEF), with a decline below the normal limit value (50%). Median follow-up duration was 54.2 months.


Of 787 patients evaluated (mean age, 50.3±9.5 years), 58 (7.4%) were developed TRCD (median time to develop TRCD, 6.1 [3.1-7.9] months) and most of them (75.9%) were improved from TRCD after 5.7 (3.5-17.7) months. TRCD patients had higher baseline blood pressure (SBP, mmHg; 125 [107-136] vs 114 [104-126], p = 0.005 and DBP, mmHg; 72 [65-81] vs 68 [61-76], p = 0.004), lower initial LVEF (63 [59-66] % vs 65 [61-68] %, p = 0.016) and more frequently administered anthracycline (98% vs 89%, p = 0.022). Cumulative dose of anthracycline was also higher in those with TRCD (404 [374-458] mg vs 372 [336-400] mg, p 5% within 3 months regardless of absolute LVEF value was more frequent in TRCD patients (78.3% vs 38.4%, p 5% within 3 months from trastuzumab administration was significantly associated with development of TRCD (HR, 45.1[17.0-127.6], p 


Asian BRCA patients received adjuvant trastuzumab were relatively young and less frequently developed TRCD compared to Western data. LVEF drop >5% within 3 months from trastuzumab administration was a strong predictor of TRCD.

Clinical trial identification

Legal entity responsible for the study

Yeon Hee Park




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.